WntResearch provides update on the preparations for the start of a Phase 2 study with the drug candidate Foxy-5
WntResearch announces today the successful completion of the process development and manufacturing of a drug formulation to be used in the continued clinical development of Foxy-5. In addition, the company has received positive preliminary results from an ongoing retrospective study, which shows that the indication for Foxy-5 in the Phase 2 study can be extended from colon cancer to colorectal cancer.Patients treated so far with Foxy-5 have received an experimental drug formulation that complicates the logistics and is unsuitable for larger studies. WntResearch has therefore devoted